HBOT Conversations:
Robert Beckman & NBIRR Study
Robert Beckman, Ph.D., Founder of the TreatNow Coalition in Arlington, Virginia, discusses the National Brain Injury Rescue Rehabilitation study focused on the use of Hyperbaric Oxygen Therapy for brain injuries. Beckman has a passion for data and helping veterans, which is what ultimately got him first involved in Hyperbaric Oxygen Therapy back in 2008. He was one of many, participating with an elite group of doctors and HBOT experts, who organized and oversaw the results of NBIRR, a multi-center HBOT trial for mild traumatic brain injury with post-concussive symptoms.
The TreatNow Coalition’s Mission is to Stop service member suicides by identifying and treating veterans and others suffering from brain wounds, TBI, PTSD, and Concussion.
Watch the Podcast
HBOT News podcast host, Edward di Girolamo, talks with guest, Robert Beckman, founder of Treatnow.org, who was instrumental in the compilation and release of The National Brain Injury Rescue and Rehabilitation Study – a multicenter observational study of hyperbaric oxygen for mild traumatic brain injury with post-concussive symptoms.
It took over a decade for that study to be completed and published. Once it was, it not only opened a door for veterans and others who were looking for a way to heal from head trauma, the NBIRR study ignited other studies to start, focusing solely on the safety & efficacy of Hyperbaric Oxygen Therapy for brain injuries.
Beckman discusses some of the challenges he has witnessed over the years, including the Army declaring that HBOT does not work. After combing through the data, Beckman states that their analysis is rooted in a “lie” about the sham they used in their study; everyone got better. This starts an in-depth conversation between di Girolamo and Beckman about the frustration of the government so easily dismissing HBOT, inflammation linked to PTSD, the stigma of PTSD being a personal and not a physical problem, the disappointment that most veterans don’t even know HBOT exists, and why more is not being done to heal our veterans from these invisible injuries of war.
Beckman proudly states that what started as nine clinics to treat veterans under the NBIRR study, has grown to about 135 clinics across the country that specialize in treating veterans with HBOT for free or reduced rates. Additionally, there are now a combined 12,500-plus success stories from these 135 clinics of individuals with TBI, PTSD, and mTBI who have completed 40 treatments/dives.
Beckman gives surgical statistics relating to HBOT and explains that by pre-oxygenating and post-oxygenating via hyperbaric chambers, patients can benefit from a 30-40% faster healing rate. He points out that countless professional athletes are now using hyperbaric oxygen therapy for faster recuperation to treat pain, injuries, and inflammation; and hyperbarics is being used all over the world right now for successfully treating COVID long-haulers. He states that COVID long-haulers are hypoxic suffering patients, and data exists that military personnel who have experienced the blow of an IUD are suffering in much of the same manner – it’s that lack of oxygen to the brain and all parts of the suffering body that HBOT helps.
di Girolamo asks the question so many of us are curious about, “If HBOT obviously works, why isn’t the military admitting to this? Why aren’t we using it more?” Beckman suggests we read this particular blog on his website that sheds much light on the subject, The Obvious Question: If HBOT works, why aren’t we using it?
Beckman reminds di Girolamo – and all of us – that this is a marathon. Yes, they’ve made great strides over the past two decades in education and research for hyperbaric oxygen therapy, but they still have a way to go. He continues to be optimistic that one day we’ll all witness our shared goal of eliminating the suicide epidemic by utilizing HBOT to thoroughly heal brain injuries.
Guest
Robert L. Beckman, Ph.D.
Dr. Beckman has been building knowledge management systems most of his professional career, primarily in the Intelligence Community and DOD. He is currently helping to run the Clinical Trial researching TBI and PTSD in brain-injured wounded warriors. He is responsible for sustaining the national network of hyperbaric clinics as well as improving the technology platform for data collection and analysis. He is a former USAF KC-135 pilot and a Vietnam Veteran.
TreatNow.org
(571) 549-4258
beckmanr88@gmail.com
Contact TreatNow.org
https://treatnow.org/
Subscribe Now, It’s Free !
Recent HBOT News
Clinical Trial – Hyperbaric Oxygenation (HBO) in Traumatic Spinal Cord Injury. (EOS) – Pilot Study
Hypothesis of the Study:
Based on the presented results, the investigator hypothesises that HBO preserves neurons that
are not irreversibly damaged (i.e. severed) during initial trauma, thus enabling regain of
their function. The investigator predicts that HBO treatment protects and enhances motor
function in initially paralysed regions, including improvement in function of the extremities
as well as recovery of urinary bladder control and bowel function.
Outline of the Proposed Study:
Within a prospective "proof of principle" trial, a total of 100 patients will be included.
Fifty patients will be recruited at the Division of Thoracic and Hyperbaric Surgery, Medical
University of Graz. In parallel, 50 control patients will be included at the Department of
Orthopaedics and Trauma, Paracelsus University Salzburg, Salzburger Landeskliniken (SALK),
Austria. Thereby, all patients that are admitted at the Medical University of Graz can be
treated and the enrolment of 50 patients into the treatment group can be implemented within
the outlined time frame. The active recruitment period is planned for three years. Both HBO
treated and control patients will undergo the same surgical and nonsurgical procedures. HBO
treatment will be started within 24 hours after the injury. A total of 21 consecutive daily
sessions will be applied, followed by routine rehabilitation programmes. By matching control
and HBO-treated patients, an evaluation of the treatment effect of HBO is possible. The
outcome will be evaluated by implementing the American Spinal Injury Association
(ASIA)-scores and magnet resonance (MR) imaging. Additionally, inflammatory and regenerative
blood markers will be analysed (neuroendocrine markers/neuro-transmitters: S100beta, Brain
Derived Neurotrophic Growth Factor [BDNF], Glial Fibrillary Acidic Protein [GFAP], Reactive
Oxygen Species (ROS), norepinephrine; array of pro- and anti-inflammatory cytokines and
chemokines).
Clinical Trial – Seated Time for 90% Incidence of Hypotension
The study will determine the 90% effective seated time after intrathecal injection of
hyperbaric bupivacaine to avoid hypotension in patients undergoing cesarean delivery.
Hyperbaric Oxygen Therapy: Exploring the Clinical Evidence.
Abstract: To provide information about hyperbaric oxygen therapy (HBOT), its mechanisms, indications and safe applications based on clinical evidence. This continuing education activity is intended for physicians, physician assistants, nurse practitioners, and nurses...